Sarepta Therapeutics Stock Earnings Reports

Key points for investors: Sarepta reports a stabilized business and reiterated full-year 2026 revenue guidance of $1.2B–$1.4B while urging prudence on upward estimate revisions given long decision cycles for a one-time gene therapy. ELEVIDYS commercial traction is recovering: management highlights growing evidence (EMBARK 1–3 year data, muscle MRI, >1,300 patients treated) and is deploying expanded commercial and educational initiatives (doubled field resources, contract sales force, new materials) to address an information gap and rebuild demand in the ambulatory population. The company is advancing a high-value siRNA pipeline with encouraging early clinical signals for SRP-1001 (FSHD) and SRP-1003 (DM1); additional MAD safety/PK/PD and early functional readouts are expected later in 2026. ELEVIDYS safety strategy: ENDEAVOR Cohort 8 (sirolimus pretreatment for non-ambulatory patients) is enrolling ~25 participants with interim real-world evidence showing no liver enzyme elevations to date; data planned by year-end and will be discussed with FDA to define next steps. PMO exon-skipping programs (EXONDYS, VYONDYS, AMONDYS) remain durable; Sarepta submitted sNDAs at end of April to convert VYONDYS and AMONDYS from accelerated to traditional approval. Financials: Q1 total product revenue $331M (ELEVIDYS $102M; PMOs $229M), total revenues $731M, GAAP and non-GAAP operating profits delivered; cash and investments ~$748M at quarter end after planned collaboration payments. Management emphasizes they can fully fund pipeline (DM1, FSHD, Huntington's, SCAs, IPF, preclinical portfolio) from internal resources without equity financing. Timelines/risks: commercial recovery is expected to be gradual (measurable improvement likely in H2 2026 into 2027), Cohort 8 regulatory path depends on data and FDA discussions, and siRNA programs still need confirmatory clinical evidence to establish registrational paths.